Aberrant activation of the PI3K and NF-κB pathways occurs frequently in human B-cell lymphomas.1, 2 Recent studies suggested reciprocal molecular interactions between these two pathways in lymphomagenesis. For example, PI3K inhibition suppresses NF-κB activity in human Burkitt’s lymphoma and diffuse large B-cell lymphoma,3, 4 while blockade of NF-κB causes suppression of PI3K activity in primary effusion lymphoma cell lines.5 Despite frequent alterations and molecular interactions of these two pathways in human lymphomas, genetic activation of anyone of these two pathways was not sufficient to initiate lymphoma development in mice.6, 7, 8
We recently reported that mutant mice (termed miR-17~92 TG mice) with B-cell-specific transgenic expression of miR-17~92, a cluster of six microRNAs (miRNAs) that are frequently upregulated in human cancers,9, 10, 11 spontaneously developed B-cell lymphomas with a high incidence.12 Subsequent molecular analyses showed that transgenic miR-17~92 expression led to constitutive activation of the PI3K and canonical NF-κB pathways by suppressing the expression of multiple negative regulators of these pathways.12 However, it remains unclear whether functional cooperation of these two pathways is sufficient to drive lymphoma development and, thereby, to mediate the lymphomagenic effect of miR-17~92 overexpression.
To directly test this, we generated B-cell-specific double transgenic mice that concurrently activate the PI3K and NF-κB pathways (CD19cre;p110*;IKK2ca mice, termed bPK mice; Figure 1a). In these mice, the PI3K pathway is activated by a p110* transgene, which encodes a constitutively active form of P110α, the catalytic subunit of PI3K,8 while the NF-κB pathway is activated by a IKK2ca transgene, which harbors two serine-to-glutamate substitution mutations in the activation loop of the kinase domain of IKK2 and constitutively activates the canonical NF-κB pathway.6 Both p110* and IKK2ca were knocked in at the Rosa26 locus with a loxP-flanked Neo-STOP cassette, which contains the neomycin resistance gene (Neo) and a transcriptional termination signal (STOP), inserted between the Rosa26 promoter and the transgene.6, 8 The CD19cre transgene drives B-cell-specific expression of the Cre recombinase, which deletes the Neo-STOP cassette and turns on the expression of these two transgenes and green fluorescent protein (GFP).
We first confirmed the expression of GFP and the activation of the PI3K and NF-κB pathways in B cells of young bPK mice. As shown in Figure 1b, the vast majority (~85%) of bPK B cells were GFP-positive. Consistently with previous reports,6, 8 both the PI3K and NF-κB pathways were active in these cells as indicated by increased phospho-AKT (S473) and phospho-S6 (S235/236) levels and IκBα degradation, respectively (Figure 1c). Similar to miR-17~92 TG mice, young bPK mice showed splenomegaly, increased splenic B-cell number and size, expanded B1 cell population (CD19+B220intCD43+CD5+), and higher percentage of λ+ B cells (Figures 1d–f).12 A majority of splenic B cells in young bPK mice were CD19+CD1d+CD21+, a phenotype similar to marginal zone B (MZB) cells in wild-type mice, recapitulating the characteristic feature of B cells in IKK2ca single transgenic mice (Figure 1f).6
We next monitored a large cohort of bPK and littermate control (p110*;IKK2ca but Cre-negative) mice for lymphoma development. As shown in Figure 2a, most of the 28 bPK mice died within 1 year (average lifespan: 8 months), whereas only one of the 26 littermate control mice died in the same period. We were able to analyze 15 sick bPK mice before they succumbed to diseases (Supplementary Table 1). These mice exhibited severe splenomegaly and hepatic granulomas (Figure 2b). Southern blot analysis showed that in 77% of these mice (10 out of 13 mice) B cells underwent mono- or oligoclonal expansion, a hallmark of lymphoma (Figure 2c; Supplementary Table 1). Consistently, these lymphoma cells were highly proliferative and were much bigger than B cells in littermate control mice (Supplementary Figure 1). B cells in these sick mice exhibited a surface phenotype of B1, MZB or both (Figures 2d and e). We have previously shown that most of miR-17~92-driven B-cell lymphomas were able to establish secondary tumors in immunodeficient mice.12 We transplanted primary B cells from seven sick bPK mice exhibiting clonal B-cell expansion into Rag1-/- mice. Among them, primary B cells from four sick bPK mice were able to establish secondary tumors in the spleen or lymph nodes of Rag1-/- mice (Supplementary Table 1). Taken together, bPK mice developed lymphomas with a high incidence and the cell surface phenotypes of B cells in sick bPK mice were similar to those of B-cell-specific miR-17~92 TG mice (Supplementary Table 1).12
In summary, we demonstrated that concurrent activation of the PI3K and NF-κB pathways is sufficient to drive lymphoma development in mice. Our previous study has shown that transgenic miR-17~92 expression activates these two pathways in B cells and leads to a high incidence of lymphomas.12 Therefore, these results suggest that the PI3K and NF-κB pathways are two major downstream pathways mediating the lymphomagenic effect of miR-17~92 overexpression. Future investigations are warranted to explore the possibility of concurrently targeting these two pathways for the treatment of lymphomas driven by elevated miR-17~92 expression.13
References
Liu P, Cheng H, Roberts TM, Zhao JJ . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627–644.
Staudt LM . Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2010; 2: a000109.
Kloo B, Nagel D, Pfeifer M, Grau M, Duwel M, Vincendeau M et al. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA 2011; 108: 272–277.
Qiao Q, Jiang Y, Li G . Inhibition of the PI3K/AKT-NF-kappaB pathway with curcumin enhanced radiation-induced apoptosis in human Burkitt's lymphoma. J Pharmacol Sci 2013; 121: 247–256.
Hussain AR, Ahmed SO, Ahmed M, Khan OS, Al Abdulmohsen S, Platanias LC et al. Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS One 2012; 7: e39945.
Sasaki Y, Derudder E, Hobeika E, Pelanda R, Reth M, Rajewsky K et al. Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity 2006; 24: 729–739.
Suzuki A, Kaisho T, Ohishi M, Tsukio-Yamaguchi M, Tsubata T, Koni PA et al. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J Exp Med 2003; 197: 657–667.
Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009; 139: 573–586.
Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004; 64: 3087–3095.
He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828–833.
Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65: 9628–9632.
Jin HY, Oda H, Lai M, Skalsky RL, Bethel K, Shepherd J et al. MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. EMBO J 2013; 32: 2377–2391.
Jin HY, Lai MY, Xiao CC . microRNA-17~92 is a powerful cancer driver and a therapeutic target. Cell Cycle 2014; 13: 495–496.
Acknowledgements
We thank Xiao lab members for discussion and critical reading of the manuscript. CX is a Pew Scholar in Biomedical Sciences. This study is supported by the PEW Charitable Trusts, Cancer Research Institute, National Institute of Health (R01AI087634, R01AI089854, RC1CA146299, R56AI110403, and R56AI121155 to CX).
Author contributions
HYJ, ML and CX designed the study. HYJ and ML performed cellular and molecular analysis of mice. JS assisted the experiments. HYJ and CX wrote the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
About this article
Cite this article
Jin, H., Lai, M., Shephard, J. et al. Concurrent PI3K and NF-κB activation drives B-cell lymphomagenesis. Leukemia 30, 2267–2270 (2016). https://doi.org/10.1038/leu.2016.204
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.204
This article is cited by
-
Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells
Cancer Chemotherapy and Pharmacology (2019)